Se connecter pour consulter les tarifs organisationnels et contractuels.
Sélectionner une taille de conditionnement
A propos de cet article
Formule empirique (notation de Hill) :
C11H16N4O4
Numéro CAS:
Poids moléculaire :
268.27
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
EC Number:
244-379-2
MDL number:
Service technique
Besoin d'aide ? Notre équipe de scientifiques expérimentés est là pour vous.
Laissez-nous vous aiderService technique
Besoin d'aide ? Notre équipe de scientifiques expérimentés est là pour vous.
Laissez-nous vous aiderInChI
1S/C11H16N4O4/c1-7(15-5-10(18)13-11(19)6-15)2-14-3-8(16)12-9(17)4-14/h7H,2-6H2,1H3,(H,12,16,17)(H,13,18,19)
InChI key
BMKDZUISNHGIBY-UHFFFAOYSA-N
SMILES string
CC(CN1CC(=O)NC(=O)C1)N2CC(=O)NC(=O)C2
assay
>98% (HPLC)
form
solid
solubility
DMSO: 40 mg/mL
storage temp.
room temp
Quality Level
Catégories apparentées
Biochem/physiol Actions
Razoxane is clinically active against angiogenesis and metastasis. Razoxane specifically inhibits topoisomerase II without inducing DNA strand breaks (topo II catalytic inhibitor). It is an antimitotic agent with immunosuppressive properties. Razoxane inhibits blood-borne and lymphatic metastases in different experimental models. Studies have shown that razoxane inhibits specifically the vasculogenic mimicry of B16F10 melanoma cells.
Razoxane is clinically active against angiogenesis and metastasis; inhibits topoisomerase II without inducing DNA strand breaks (topo II catalytic inhibitor).
Classe de stockage
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Faites votre choix parmi les versions les plus récentes :
Déjà en possession de ce produit ?
Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.
W Rhomberg et al.
Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 175(3), 102-104 (1999-03-27)
Angiosarcomas of the heart are rare neoplasms bearing an unfavorable prognosis. In recent series, the median survival is about 5 months. The response to radiation therapy is uncertain. A 65-year-old copper smith with an angiosarcoma of the right atrium and
K Hellmann et al.
Cancer treatment reviews, 18(4), 225-240 (1991-12-01)
Razoxane blocks cell division in the G2/M phase of the cell generation cycle and appears to normalize tumour neovasculature development. These were the principal reasons for the examination and probably for the demonstration of the radiosensitizing activity of Rz. Specially
Dynamics of tumour angiogenesis: effect of razoxane-induced growth rate slowdown.
K Hellmann
Clinical & experimental metastasis, 20(2), 95-102 (2003-04-23)
M Doornaert et al.
Acta chirurgica Belgica, 113(1), 1-7 (2013-04-05)
Extravasation is a devastating complication of intravenous therapy that develops when a drug infiltrates the interstitial tissue surrounding the vein. Due to the uncertain and possibly dramatic outcome, early recognition and adequate treatment with the aid of a standardized protocol
Daniel Stromberg et al.
Annals of the New York Academy of Sciences, 1270, 59-65 (2012-10-12)
Neonates and infants undergoing heart surgery with cardioplegic arrest experience both inflammation and myocardial ischemia-reperfusion (IR) injury. These processes provoke myocardial apoptosis and oxygen-free radical formation that result in cardiac injury and dysfunction. Thymosin β4 (Tβ4) is a naturally occurring
Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..
Contacter notre Service technique